Unclaimed brand
ImmunoACT delivers India’s leading CAR-T cell therapy for blood cancer treatment, lymphoma treatment, and leukemia care. Learn how indigenous CAR-T advances affordable cancer treatment nationwide.
Liking this brand profile? Share this page
Hex Code
Color name
RGB
HSL
CMYK
#13A529
La Palma
19, 165, 41
129, 79, 36
88, 0, 75, 35
#DFA761
Di Serria
223, 167, 97
33, 66, 63
0, 25, 57, 13
#305595
St Tropaz
48, 85, 149
218, 51, 39
68, 43, 0, 42
ImmunoACT is an Indian biotechnology company developing and delivering CAR-T cell therapies for cancer. Established in 2018 as a spin-off from IIT Bombay, the company builds on research begun in 2013 and has developed its proprietary platform and manufacturing capabilities in India. Its flagship therapy, NexCAR19, is described as India’s first approved CAR-T treatment and is intended for certain B-cell cancers, including acute lymphoblastic leukemia and large B-cell lymphoma. The treatment modifies a patient’s own immune cells to recognize and attack cancer cells.
ImmunoACT’s work spans research, clinical development, manufacturing, and support for treatment delivery. Its integrated platform includes in-house production capabilities, and its WHO-certified GMP facility is designed to supply cell and gene therapies. The company works with more than 130 authorised cancer treatment centres in India and provides clinician-focused support. It also advances a pipeline of therapies and collaborates with academic, healthcare, and commercial partners. Through a partnership with Cipla, ImmunoACT is working to expand access to talicabtagene autoleucel in South Africa, Algeria, and Morocco.
Company type
Privately Held
Year founded
2018
Company size
51-200 employees
The ImmunoACT name, logos and brand assets are trademarks of ImmunoACT and its affiliates. Brandfetch isn't affiliated with or endorsed by ImmunoACT. Their use is subject to ImmunoACT's brand guidelines.
